Aclaris Therapeutics (ACRS) AI Stock Analysis

• Market Cap: $155.92M
• Dividend Yield: N/A
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -40.09%
• EPS Growth: -18.67%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.12
• Shares Outstanding: 108,281,240
• 10 Day Avg. Volume: 1,937,861
• 30 Day Avg. Volume: 1,136,576
• PEG Ratio: 0.36
• Price to Book (P/B): 5.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.07
• Enterprise Value/Market Cap: 6.30
• Enterprise Value/Revenue: 10.28
• Enterprise Value/Gross Profit: 268.89
• Enterprise Value/Ebitda: -3.95
• 1Y Price Target: $9.40
• Price Target Upside: 552.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 46 Neutral
• Price Target: ―

Aclaris Therapeutics is currently facing significant challenges, with a primary focus on its financial performance. The company's lack of profitability and reliance on external financing are major concerns. The technical analysis further underscores negative momentum, although oversold indicators might suggest a potential short-term rebound. Valuation is unattractive due to negative earnings, and no significant earnings call data or corporate events are available to offset these issues.

Positive Factors

Clinical Trial Results

The single-arm Phase 2a results in patients with moderate-to-severe AD demonstrated improvements in efficacy measures, with 94% of participants achieving EASI-75 scores and 88% having clear or nearly clear skin.

Financial Stability

ACRS has a cash runway into 2028, supporting its operations for several more years, which provides financial stability to continue its research and development efforts.

Pipeline Progress

Aclaris Therapeutics has made significant progress with its pipeline, including the initiation of a placebo-controlled Phase 1a/1b program for ATI-052, a potential best-in-class investigational antibody.

Negative Factors

Clinical Trial Concerns

The lack of a placebo control in the open-label Phase 2a trial for '045 requires caution, despite promising data.

Competitive Landscape

Investors are cautious about the competitive landscape, as Teze's discontinuation in AD raises questions about the challenges in TSLP inhibition despite promising data for '045.

Aclaris Therapeutics Business Overview & Revenue Model

Company Description

Aclaris Therapeutics, Inc. is a biopharmaceutical company that operates in the healthcare sector, focusing on the development and commercialization of innovative therapies for dermatological and immuno-inflammatory diseases. The company is engaged in the research and development of small molecule therapies that aim to address significant unmet medical needs. Aclaris's core products include drug candidates targeting specific enzymes and pathways relevant to dermatological conditions, such as alopecia areata and vitiligo.

How the Company Makes Money

Aclaris Therapeutics makes money primarily through the development and potential commercialization of its proprietary drug candidates. The company's revenue model includes milestones and royalty payments from partnerships with larger pharmaceutical companies that collaborate on the development and commercialization of Aclaris's therapies. Additionally, Aclaris may earn revenue from out-licensing its technologies and intellectual property, as well as from any approved products sold directly to the market. The company's earnings are significantly influenced by the successful advancement of its drug candidates through clinical trials and regulatory approvals, as well as strategic partnerships that provide funding for development activities.

Aclaris Therapeutics Financial Statement Overview

Summary

Aclaris Therapeutics faces significant challenges in achieving profitability and positive cash flow, despite a strong balance sheet with no debt and substantial cash reserves. Revenue growth is inconsistent, and ongoing losses suggest a need for strategic changes to improve operational efficiency. The company's ability to maintain financial health is contingent on continued access to external financing and cost management improvements.

Income Statement

Aclaris Therapeutics has experienced fluctuating revenue growth, with a decline from 2023 to 2024. The company struggles with profitability, indicated by substantial negative EBIT, EBITDA, and net income margins. Gross profit margin is relatively high, suggesting effective cost management at the gross level, but significant operating losses highlight challenges in controlling other expenses.

Balance Sheet

The balance sheet displays a strong equity position with zero debt in 2024, leading to a healthy equity ratio. However, consistent losses have eroded equity over time. The company maintains significant cash reserves which provide a buffer against operational losses, but the lack of profitability poses a long-term risk.

Cash Flow

Cash flow analysis reveals negative operating cash flow, indicating a reliance on external financing to sustain operations. Free cash flow remains negative, although there is a slight improvement in cash flow stability compared to previous years. The company is capable of raising capital, as evidenced by positive financing cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.78M	18.72M	31.25M	29.75M	6.76M	6.48M
Gross Profit	3.65M	3.46M	13.17M	17.79M	2.05M	1.35M
EBITDA	-54.12M	-51.72M	-117.56M	-84.36M	-65.06M	-48.20M
Net Income	-130.21M	-132.06M	-88.48M	-88.66M	-114.28M	-51.15M
Balance Sheet
Total Assets	198.09M	220.33M	197.41M	254.60M	251.21M	70.78M
Cash, Cash Equivalents and Short-Term Investments	105.31M	113.59M	119.11M	229.81M	225.66M	54.13M
Total Debt	0.00	0.00	426.00K	684.00K	693.00K	11.26M
Total Liabilities	54.03M	64.77M	40.23M	56.98M	53.87M	33.13M
Stockholders Equity	144.07M	155.55M	157.18M	197.62M	197.34M	37.65M
Cash Flow
Free Cash Flow	-48.16M	-20.20M	-79.63M	-68.17M	-52.44M	-39.09M
Operating Cash Flow	-12.32M	-20.07M	-78.33M	-67.57M	-52.13M	-38.63M
Investing Cash Flow	-67.48M	-69.77M	46.22M	12.63M	-167.63M	6.39M
Financing Cash Flow	74.32M	74.54M	26.71M	72.87M	225.05M	18.37M

Aclaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.44
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Negative. The current price of 1.44 is below the 20-day moving average (MA) of 1.48, above the 50-day MA of 1.39, and below the 200-day MA of 1.94, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 49.27 is Neutral, neither overbought nor oversold. The STOCH value of 29.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACRS.

Aclaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	51 Neutral	$196.42M	―	-32.97%	―	―	―
TLSI	50 Neutral	$192.54M	―	271.41%	―	85.03%	53.73%
ACRS	46 Neutral	$155.92M	―	-91.03%	―	-40.09%	-18.67%
Sector *	46 Neutral	C$194.71M	-4.33	-8.58%	2.64%	13.66%	-0.73%
IPHA	45 Neutral	$165.65M	―	-160.99%	―	-75.67%	-552.37%
MOLN	45 Neutral	$150.75M	―	-40.40%	―	-67.23%	4.11%
TARA	39 Underperform	$111.50M	―	-41.88%	―	―	32.58%

Aclaris Therapeutics Corporate Events

Aclaris Therapeutics Highlights Drug Progress and Financial Strength

Aclaris Therapeutics has updated its corporate overview presentation, highlighting the progress and potential of its drug candidates, including ATI-045, ATI-052, and ATI-2138. The company is well-positioned financially, with a strong cash runway expected to support operations into 2028, and is leveraging its expertise in small and large molecule discovery to advance its pipeline. This update suggests a solid trajectory for Aclaris in its market, potentially enhancing its position in the biotechnology industry and providing significant opportunities for stakeholders.